<DOC>
	<DOC>NCT01449370</DOC>
	<brief_summary>The purpose of this study is to determine the maximum tolerated dose (MTD) and/or optimal biologic dose(OBD), safety and tolerability, dose-limiting toxicity (DLT) of TAK-117 when administered orally in subjects with advanced solid malignancies.</brief_summary>
	<brief_title>Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Subjects have had their PIK3CA gene mutation status assessed prior to enrolling into the study Subjects must have documented disease progression prior to enrolling into the study locally advanced or metastatic solid tumors with the exception of primary brain tumor, and have failed or are not eligible for standard of care therapy. Age greater than or equal to (&gt;=) 18 years, including males and females; Eastern cooperative oncology group (ECOG) performance status (PS) 01; Adequate organ function; Male subjects must be surgically sterile or must agree to use physicianapproved contraception during the study and for 30 days following the last study drug administration; Ability to swallow oral medications; Ability to understand and willingness to sign informed consent prior to initiation of any study procedures; For women of childbearing potential, negative serum pregnancy test within 14 days prior to the first study drug administration and use of physicianapproved method of birth control from 30 days prior to the first study drug administration to 30 days following the last study drug administration Diagnosis of primary brain tumor; untreated brain metastasis or history of leptomeningeal disease or spinal cord compression; Received prior cancer or other investigational therapy within 2 weeks prior to the first administration of study drug; Have received a systemic corticosteroid within one week prior to the first administration of study drug; Clinically significant cardiac disease; Myocardial infarction or unstable angina within 6 months prior to the first administration of study drug; Malabsorption ; Poorly controlled diabetes mellitus; Pregnancy (positive serum or urine pregnancy test) or breast feeding; Untreated brain metastasis or history of leptomeningeal disease or spinal cord compression; Failed to recover from the reversible effects of prior anticancer therapies; Have received a selective phosphoinositide3kinase alpha isoform (PI3Kalpha) inhibitor Other clinically significant comorbidities, such as uncontrolled pulmonary disease, active central nervous system (CNS) disease, active infection, or any other condition that could compromise the subject's participation in the study Known human immunodeficiency virus (HIV) infection Have a secondary malignancy within the last 3 years prior to first dose of study drug, excluding treated nonmelanoma skin cancer, carcinoma in situ, or locallytreated prostate cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>INK1117</keyword>
	<keyword>PIK3CA</keyword>
	<keyword>KINASE</keyword>
	<keyword>TUMOR</keyword>
	<keyword>CANCER</keyword>
	<keyword>Locally advanced or metastatic solid tumors</keyword>
	<keyword>not eligible for standard of care therapy</keyword>
</DOC>